Physician profile

Kandice Bailey

Dermatopathology (Dermatology) · Nashville, TN

NPI 1760011480

$1,492.85

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,389.26

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
E.R. Squibb & Sons, L.L.C. $427.66 2023-2024 Sotyktu
Abbvie INC. $312.38 2022-2024 Rinvoq, Skyrizi
Boehringer Ingelheim Pharmaceuticals, INC. $218.89 2024 Spevigo
Janssen Biotech, INC. $130.01 2024 Tremfya
Incyte Corporation $112.99 2024 Opzelura
Amgen INC. $111.62 2024 Otezla
Regeneron Healthcare Solutions, INC. $109.85 2024
Krystal Biotech INC $69.45 2024 Vyjuvek

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Kandice Bailey

$1,492.85

in general payments reported 2019-2025

Years
2022-2024
Top company
E.R. Squibb & Sons, L.L.C.

https://glasscript.com/doctor/11422384/kandice-bailey

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.